Loading
A phase 2 trial of Osimertinib, Carboplatin, Cisplatin and Pemetrexed in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations is a phase 2 interventional study registered as NCT06194448 by AstraZeneca, with 76 participants enrolled, started 2024-04-21 and due to reach its primary completion in 2026-07-07. Interventions recorded: Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel and Radiation.
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, Pemetrexed, AstraZeneca, Cisplatin and the tag pipeline.
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, Pemetrexed, Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.